A citation-based method for searching scientific literature

Konstantinos Georgiou, Longyun Chen, Mattias Berglund, Weicheng Ren, Noel F C C de Miranda, Susana Lisboa, Marco Fangazio, Shida Zhu, Yong Hou, Kui Wu, Wenfeng Fang, Xianhuo Wang, Bin Meng, Li Zhang, Yixin Zeng, Govind Bhagat, Magnus Nordenskjöld, Christer Sundström, Gunilla Enblad, Riccardo Dalla-Favera, Huilai Zhang, Manuel R Teixeira, Laura Pasqualucci, Roujun Peng, Qiang Pan-Hammarström. Blood 2016
Times Cited: 131







List of co-cited articles
1500 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Junichi Kiyasu, Hiroaki Miyoshi, Akie Hirata, Fumiko Arakawa, Ayako Ichikawa, Daisuke Niino, Yasuo Sugita, Yuji Yufu, Ilseung Choi, Yasunobu Abe,[...]. Blood 2015
316
57

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Michael R Green, Stefano Monti, Scott J Rodig, Przemyslaw Juszczynski, Treeve Currie, Evan O'Donnell, Bjoern Chapuy, Kunihiko Takeyama, Donna Neuberg, Todd R Golub,[...]. Blood 2010
844
43

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Benjamin J Chen, Bjoern Chapuy, Jing Ouyang, Heather H Sun, Margaretha G M Roemer, Mina L Xu, Hongbo Yu, Christopher D M Fletcher, Gordon J Freeman, Margaret A Shipp,[...]. Clin Cancer Res 2013
582
40

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Alexander M Lesokhin, Stephen M Ansell, Philippe Armand, Emma C Scott, Ahmad Halwani, Martin Gutierrez, Michael M Millenson, Adam D Cohen, Stephen J Schuster, Daniel Lebovic,[...]. J Clin Oncol 2016
687
37

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Stephen M Ansell, Alexander M Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C Scott, Martin Gutierrez, Stephen J Schuster, Michael M Millenson, Deepika Cattry, Gordon J Freeman,[...]. N Engl J Med 2015
36

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Margaretha G M Roemer, Ranjana H Advani, Azra H Ligon, Yasodha Natkunam, Robert A Redd, Heather Homer, Courtney F Connelly, Heather H Sun, Sarah E Daadi, Gordon J Freeman,[...]. J Clin Oncol 2016
483
35

Targetable genetic features of primary testicular and primary central nervous system lymphomas.
Bjoern Chapuy, Margaretha G M Roemer, Chip Stewart, Yuxiang Tan, Ryan P Abo, Liye Zhang, Andrew J Dunford, David M Meredith, Aaron R Thorner, Ekaterina S Jordanova,[...]. Blood 2016
305
34

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
A A Alizadeh, M B Eisen, R E Davis, C Ma, I S Lossos, A Rosenwald, J C Boldrick, H Sabet, T Tran, X Yu,[...]. Nature 2000
30

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Christine P Hans, Dennis D Weisenburger, Timothy C Greiner, Randy D Gascoyne, Jan Delabie, German Ott, H Konrad Müller-Hermelink, Elias Campo, Rita M Braziel, Elaine S Jaffe,[...]. Blood 2004
29

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.
Michael R Green, Scott Rodig, Przemyslaw Juszczynski, Jing Ouyang, Papiya Sinha, Evan O'Donnell, Donna Neuberg, Margaret A Shipp. Clin Cancer Res 2012
476
29

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Bjoern Chapuy, Chip Stewart, Andrew J Dunford, Jaegil Kim, Atanas Kamburov, Robert A Redd, Mike S Lawrence, Margaretha G M Roemer, Amy J Li, Marita Ziepert,[...]. Nat Med 2018
754
28

Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
Dohee Kwon, Sehui Kim, Pil-Jong Kim, Heounjeong Go, Soo Jeong Nam, Jin Ho Paik, Young A Kim, Tae Min Kim, Dae Seog Heo, Chul Woo Kim,[...]. Histopathology 2016
109
27

Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.
David D W Twa, Fong Chun Chan, Susana Ben-Neriah, Bruce W Woolcock, Anja Mottok, King L Tan, Graham W Slack, Jay Gunawardana, Raymond S Lim, Andrew W McPherson,[...]. Blood 2014
206
26

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Anupama Reddy, Jenny Zhang, Nicholas S Davis, Andrea B Moffitt, Cassandra L Love, Alexander Waldrop, Sirpa Leppa, Annika Pasanen, Leo Meriranta, Marja-Liisa Karjalainen-Lindsberg,[...]. Cell 2017
561
26

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Roland Schmitz, George W Wright, Da Wei Huang, Calvin A Johnson, James D Phelan, James Q Wang, Sandrine Roulland, Monica Kasbekar, Ryan M Young, Arthur L Shaffer,[...]. N Engl J Med 2018
881
26

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
Stephen M Ansell, Monique C Minnema, Peter Johnson, John M Timmerman, Philippe Armand, Margaret A Shipp, Scott J Rodig, Azra H Ligon, Margaretha G M Roemer, Nishitha Reddy,[...]. J Clin Oncol 2019
181
26

Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Keisuke Kataoka, Yuichi Shiraishi, Yohei Takeda, Seiji Sakata, Misako Matsumoto, Seiji Nagano, Takuya Maeda, Yasunobu Nagata, Akira Kitanaka, Seiya Mizuno,[...]. Nature 2016
403
25

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Steven H Swerdlow, Elias Campo, Stefano A Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A Salles, Andrew D Zelenetz,[...]. Blood 2016
24

Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.
Madhavi Challa-Malladi, Yen K Lieu, Olivia Califano, Antony B Holmes, Govind Bhagat, Vundavalli V Murty, David Dominguez-Sola, Laura Pasqualucci, Riccardo Dalla-Favera. Cancer Cell 2011
293
24

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
David J Andorsky, Reiko E Yamada, Jonathan Said, Geraldine S Pinkus, David J Betting, John M Timmerman. Clin Cancer Res 2011
256
24

PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
Lakshmi Nayak, Fabio M Iwamoto, Ann LaCasce, Srinivasan Mukundan, Margaretha G M Roemer, Bjoern Chapuy, Philippe Armand, Scott J Rodig, Margaret A Shipp. Blood 2017
251
23

Stromal gene signatures in large-B-cell lymphomas.
G Lenz, G Wright, S S Dave, W Xiao, J Powell, H Zhao, W Xu, B Tan, N Goldschmidt, J Iqbal,[...]. N Engl J Med 2008
22

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
Christian Steidl, Sohrab P Shah, Bruce W Woolcock, Lixin Rui, Masahiro Kawahara, Pedro Farinha, Nathalie A Johnson, Yongjun Zhao, Adele Telenius, Susana Ben Neriah,[...]. Nature 2011
408
22

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
Andreas Rosenwald, George Wright, Wing C Chan, Joseph M Connors, Elias Campo, Richard I Fisher, Randy D Gascoyne, H Konrad Muller-Hermelink, Erlend B Smeland, Jena M Giltnane,[...]. N Engl J Med 2002
21

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.
Ryan D Morin, Maria Mendez-Lago, Andrew J Mungall, Rodrigo Goya, Karen L Mungall, Richard D Corbett, Nathalie A Johnson, Tesa M Severson, Readman Chiu, Matthew Field,[...]. Nature 2011
20

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
Pier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, Jean-Marie Michot, John Kuruvilla, Arun Balakumaran, Yayan Zhang, Sabine Chlosta, Margaret A Shipp, Philippe Armand. Blood 2017
202
19

PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
Wei Xing, Karen Dresser, Rui Zhang, Andrew M Evens, Hongbo Yu, Bruce A Woda, Benjamin J Chen. Oncotarget 2016
45
40

PD-1 and its ligands in tolerance and immunity.
Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe. Annu Rev Immunol 2008
18

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.
D Rossille, M Gressier, D Damotte, D Maucort-Boulch, C Pangault, G Semana, S Le Gouill, C Haioun, K Tarte, T Lamy,[...]. Leukemia 2014
242
18

Oncogenically active MYD88 mutations in human lymphoma.
Vu N Ngo, Ryan M Young, Roland Schmitz, Sameer Jhavar, Wenming Xiao, Kian-Huat Lim, Holger Kohlhammer, Weihong Xu, Yandan Yang, Hong Zhao,[...]. Nature 2011
18

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
Christopher D Carey, Daniel Gusenleitner, Mikel Lipschitz, Margaretha G M Roemer, Edward C Stack, Evisa Gjini, Xihao Hu, Robert Redd, Gordon J Freeman, Donna Neuberg,[...]. Blood 2017
192
18

Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
Thomas Menter, Andrea Bodmer-Haecki, Stephan Dirnhofer, Alexandar Tzankov. Hum Pathol 2016
105
17

Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.
Min Shi, Margaretha G M Roemer, Bjoern Chapuy, Xiaoyun Liao, Heather Sun, Geraldine S Pinkus, Margaret A Shipp, Gordon J Freeman, Scott J Rodig. Am J Surg Pathol 2014
109
17

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Robert Chen, Pier Luigi Zinzani, Michelle A Fanale, Philippe Armand, Nathalie A Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P Vassilakopoulos,[...]. J Clin Oncol 2017
624
17

Analysis of the coding genome of diffuse large B-cell lymphoma.
Laura Pasqualucci, Vladimir Trifonov, Giulia Fabbri, Jing Ma, Davide Rossi, Annalisa Chiarenza, Victoria A Wells, Adina Grunn, Monica Messina, Oliver Elliot,[...]. Nat Genet 2011
730
16

The tumour microenvironment in B cell lymphomas.
David W Scott, Randy D Gascoyne. Nat Rev Cancer 2014
311
16

PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.
James Godfrey, Sravya Tumuluru, Riyue Bao, Michael Leukam, Girish Venkataraman, John Phillip, Carrie Fitzpatrick, James McElherne, Brendan W MacNabb, Robert Orlowski,[...]. Blood 2019
59
27

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
Philippe Armand, Margaret A Shipp, Vincent Ribrag, Jean-Marie Michot, Pier Luigi Zinzani, John Kuruvilla, Ellen S Snyder, Alejandro D Ricart, Arun Balakumaran, Shelonitda Rose,[...]. J Clin Oncol 2016
463
14

High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma.
Joaquim Carreras, Armando Lopez-Guillermo, Giovanna Roncador, Neus Villamor, Lluis Colomo, Antonio Martinez, Rifat Hamoudi, William J Howat, Emili Montserrat, Elias Campo. J Clin Oncol 2009
228
14

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Anas Younes, Armando Santoro, Margaret Shipp, Pier Luigi Zinzani, John M Timmerman, Stephen Ansell, Philippe Armand, Michelle Fanale, Voravit Ratanatharathorn, John Kuruvilla,[...]. Lancet Oncol 2016
646
14

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
R Eric Davis, Vu N Ngo, Georg Lenz, Pavel Tolar, Ryan M Young, Paul B Romesser, Holger Kohlhammer, Laurence Lamy, Hong Zhao, Yandan Yang,[...]. Nature 2010
14

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.
Lisa M Rimsza, Robin A Roberts, Thomas P Miller, Joseph M Unger, Michael LeBlanc, Rita M Braziel, Dennis D Weisenberger, Wing C Chan, H Konrad Muller-Hermelink, Elaine S Jaffe,[...]. Blood 2004
251
14

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Zijun Y Xu-Monette, Jianfeng Zhou, Ken H Young. Blood 2018
215
14

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
Wei Ding, Betsy R LaPlant, Timothy G Call, Sameer A Parikh, Jose F Leis, Rong He, Tait D Shanafelt, Sutapa Sinha, Jennifer Le-Rademacher, Andrew L Feldman,[...]. Blood 2017
242
13

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Zijun Y Xu-Monette, Lin Wu, Carlo Visco, Yu Chuan Tai, Alexander Tzankov, Wei-min Liu, Santiago Montes-Moreno, Karen Dybkaer, April Chiu, Attilio Orazi,[...]. Blood 2012
232
13

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.
Jens G Lohr, Petar Stojanov, Michael S Lawrence, Daniel Auclair, Bjoern Chapuy, Carrie Sougnez, Peter Cruz-Gordillo, Birgit Knoechel, Yan W Asmann, Susan L Slager,[...]. Proc Natl Acad Sci U S A 2012
708
13

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wyndham H Wilson, Ryan M Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga, George Wright, Chih-Jian Lih, P Mickey Williams, Arthur L Shaffer, John Gerecitano,[...]. Nat Med 2015
713
13

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.
Daisuke Ennishi, Katsuyoshi Takata, Wendy Béguelin, Gerben Duns, Anja Mottok, Pedro Farinha, Ali Bashashati, Saeed Saberi, Merrill Boyle, Barbara Meissner,[...]. Cancer Discov 2019
137
13

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Philippe Armand, Andreas Engert, Anas Younes, Michelle Fanale, Armando Santoro, Pier Luigi Zinzani, John M Timmerman, Graham P Collins, Radhakrishnan Ramchandren, Jonathon B Cohen,[...]. J Clin Oncol 2018
372
13

A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.
George W Wright, Da Wei Huang, James D Phelan, Zana A Coulibaly, Sandrine Roulland, Ryan M Young, James Q Wang, Roland Schmitz, Ryan D Morin, Jeffrey Tang,[...]. Cancer Cell 2020
270
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.